Medical technology

Worldwide Drug-Eluting Stents Industry to 2027 - Surge in Demand for Minimally Invasive Surgical Procedures is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 25, 2021
Surgery, Health, Medical devices, Interventional cardiology, Medicine, Medical technology, Drug-eluting stent, Medical devices, Clinical medicine, Stent, Bare-metal stent, Percutaneous coronary intervention

Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages.

Key Points: 
  • Drug-eluting stents (DES) are small cylindrical stents that aid in improving blood flow through arteries to heart by minimizing blockages.
  • Polymer-based drug-eluting coating stents are designed to allow consistent and controlled release of drug from stent surface into arteries.
  • Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market growth during the forecast period.
  • Profiles and growth strategies of key players are thoroughly analyzed to understand the competitive outlook of the global market.

The Alliance for Artificial Intelligence in Healthcare Adds Google, Roche as Members to Advocate for Solutions to the World's Biggest Health Challenges

Retrieved on: 
Tuesday, May 25, 2021
Health, Health informatics, Telehealth, Medical technology, Digital health, Artificial intelligence in healthcare, Medical device, Articles, Patient safety, Draft:ICT4Health

Founded in 2018, AAIH is the leading international advocacy organization for the responsible adoption and application of AI/ML technologies across the healthcare umbrella.

Key Points: 
  • Founded in 2018, AAIH is the leading international advocacy organization for the responsible adoption and application of AI/ML technologies across the healthcare umbrella.
  • By bringing together stakeholders from industry, government, academia, and finance, AAIH seeks to foster changes that result in the best outcomes for patients.
  • The Alliance for Artificial Intelligence in Healthcare (AAIH) is an international advocacy organization dedicated to the responsible adoption and application of AI/ML in healthcare.
  • Our members represent all healthcare sectors, including drug R&D, digital health, medical devices, healthcare delivery, data science & technology providers with a shared goal of improving the state of healthcare globally through AI-enabled solutions.

amg International GmbH, a Q3 Medical Devices Ltd Company, Receives European CE Mark Approval for UNITY-B™ Biodegradable Stent

Retrieved on: 
Monday, May 24, 2021
Interventional radiology, Stent, Medical technology, Medicine, Biodegradation, Interventional cardiology, Medical equipment, Dual therapy stent

The Company announced that it has received CE Mark approval for its second fully biodegradable product, the UNITY-B balloon expandable biodegradable biliary stent (BEBS) for endoscopic use.

Key Points: 
  • The Company announced that it has received CE Mark approval for its second fully biodegradable product, the UNITY-B balloon expandable biodegradable biliary stent (BEBS) for endoscopic use.
  • The UNITY-B Biodegradable implant was developed as a complimentary biodegradable metallic stent to amg's ARCHIMEDES biodegradable pancreaticobiliary stent, which is currently available in fast, medium, and long-lasting degradation profiles.
  • ARCHIMEDES obtained CE mark approval in 2018 and was subsequently launched through a global distribution partnership with Medtronic.
  • "The CE mark approval of the UNITY-B stent represents yet another milestone for amg International and all the companies of Q3 Medical and our mission to 'Create Value By Helping People'.

ITC Formally Commences Investigation into Apple Watch Infringement of AliveCor Patents

Retrieved on: 
Friday, May 21, 2021
Medicine, Medical technology, Branches of biology, Alivecor, Apple Inc., Apple Watch, Electrocardiography

b'MOUNTAIN VIEW, Calif., May 21, 2021 /PRNewswire/ -- AliveCor , a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services, today announced that the US International Trade Commission (ITC) issued a Notice of Institution of an Investigation into Apple\'s alleged infringement of three AliveCor patents.

Key Points: 
  • b'MOUNTAIN VIEW, Calif., May 21, 2021 /PRNewswire/ -- AliveCor , a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services, today announced that the US International Trade Commission (ITC) issued a Notice of Institution of an Investigation into Apple\'s alleged infringement of three AliveCor patents.
  • Last month, AliveCor filed the case with ITC, alleging the infringement and seeking to bar the importation of Apple Watches incorporating the infringing technology into the United States.\nThe ITC announcement came late Thursday and commences an inquiry into whether Apple illegally incorporated AliveCor\'s patented electrocardiogram monitor technology into the Apple Watch.\nAliveCor, Inc. is transforming cardiological care using deep learning.
  • AliveCor protects its customers with stringent data security and compliance practices , achieving HIPAA compliance and SOC2 Type 1 and Type 2 attestations.
  • AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers.

Global Femtech Solutions Industry Report 2021: The COVID-19 Pandemic and a Rising Focus on Women's Untapped Healthcare Needs are Transforming the Industry - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Biotechnology, Health, Women, Consumer, Occupational safety and health, Articles, Health, Contemporary history, Medical technology, Women's health, Femtech, Impact of the COVID-19 pandemic, COVID-19 pandemic, COVID-19

b'The "The COVID-19 Pandemic and a Rising Focus on Women\'s Untapped Healthcare Needs are Transforming the Global Femtech Solutions Industry" report has been added to ResearchAndMarkets.com\'s offering.\nThis research study analyses the impact of the COVID-19 pandemic on women\xe2\x80\x99s healthcare and focuses on the different segments in women\xe2\x80\x99s health.

Key Points: 
  • b'The "The COVID-19 Pandemic and a Rising Focus on Women\'s Untapped Healthcare Needs are Transforming the Global Femtech Solutions Industry" report has been added to ResearchAndMarkets.com\'s offering.\nThis research study analyses the impact of the COVID-19 pandemic on women\xe2\x80\x99s healthcare and focuses on the different segments in women\xe2\x80\x99s health.
  • The pandemic has also laid bare the extent to which there is a dearth of solutions available for specific women\xe2\x80\x99s health issues such as fibroids, PCOS, thyroid issues, endometriosis, pelvic health, pre-menopausal, and menopausal care.
  • The study provides an analysis of the femtech funding landscape along with a comparative analysis of femtech funding and digital health funding.
  • The study also provides revenue forecasts and a comparative analysis of pre-COVID-19 and post COVID-19 revenue projections.

Laurel Bridge Software announces support for RESTful DICOMweb™

Retrieved on: 
Thursday, May 20, 2021
Medical imaging, Health, DICOM, Articles, Picture archiving and communication system, Workflow, Medical technology

b'NEWARK, Del., May 20, 2021 /PRNewswire/ --Laurel Bridge Software, a provider of imaging software solutions that enable health systems to orchestrate their medical imaging workflows, announces support for RESTful DICOMweb services as part of a significant software upgrade for their CompassTM - Routing Workflow Manager .\nSupport for RESTful DICOMweb services is important because it supports a significant industry trend towards cloud based medical imaging workflows that are designed around DICOMweb technology.

Key Points: 
  • b'NEWARK, Del., May 20, 2021 /PRNewswire/ --Laurel Bridge Software, a provider of imaging software solutions that enable health systems to orchestrate their medical imaging workflows, announces support for RESTful DICOMweb services as part of a significant software upgrade for their CompassTM - Routing Workflow Manager .\nSupport for RESTful DICOMweb services is important because it supports a significant industry trend towards cloud based medical imaging workflows that are designed around DICOMweb technology.
  • Most existing PACS and imaging modalities do not support RESTful DICOMweb services, however, there is an increasing requirement for such devices to communicate with cloud-based applications and devices.The now available DICOMweb support enables the integration of traditional DICOM and DICOMweb.
  • The accelerated adoption of cloud-based archives and applications, including integration with AI algorithms and research initiatives, are driving this requirement.\nThis new software provides the following benefits:\n"We have seen RESTful services move from the periphery into the mainstream of medical imaging workflow", says Jeff Blair, President of Laurel Bridge Software.
  • It is but one of the many components in the Laurel Bridge Enterprise Imaging Workflow Suite.\nFor over 20 years, Laurel Bridge Software has been providing healthcare organizations with enterprise imaging workflow solutions for image routing, prior exam fetching, migration, and modality worklist management.

Orchestra BioMed™ Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy™

Retrieved on: 
Monday, May 17, 2021
Branches of biology, Cardiovascular physiology, Medical technology, Biology, Cardiac electrophysiology, Medical devices, Biomedical engineering, Embedded systems, Afterload, Artificial cardiac pacemaker, Preload, BioMed Central

Of the 26 treatment patients, 25 completed 18 months of follow-up (one patient died of cancer) and 17 reached 24 months of therapy to date.

Key Points: 
  • Of the 26 treatment patients, 25 completed 18 months of follow-up (one patient died of cancer) and 17 reached 24 months of therapy to date.
  • Orchestra BioMed\xe2\x80\x99s CE Mark-approved Moderato\xc2\xae implantable pulse generator system delivers BackBeat CNT while also providing standard pacemaker functions.
  • BackBeat CNT mimics the effects of multi-drug hypertension therapy by targeting preload, afterload and sympathetic tone.
  • Orchestra BioMed was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by the Company\xe2\x80\x99s founding team.

Global Artificial Intelligence in Healthcare Markets Report 2021: Growing Investment in AI Healthcare Start-ups & Increasing Cross-Industry Partnerships and Collaborations

Retrieved on: 
Friday, May 14, 2021
Articles, Academic disciplines, Medical technology, Computer-assisted surgery, Robot-assisted surgery, Telemedicine, Artificial intelligence in healthcare, Applications of artificial intelligence, Robotics, Robot, Surgery, Artificial intelligence

The growth of the artificial intelligence in healthcare market is attributed to the rising application of artificial intelligence in healthcare, growing investment in AI healthcare start-ups, and increasing cross-industry partnerships and collaborations.

Key Points: 
  • The growth of the artificial intelligence in healthcare market is attributed to the rising application of artificial intelligence in healthcare, growing investment in AI healthcare start-ups, and increasing cross-industry partnerships and collaborations.
  • The clinical trials segment held the largest market share in 2019, and the robot assisted surgery segment is estimated to register the highest CAGR during the forecast period.
  • Rising adoption of robotic surgeries due to better surgical outcomes offer lucrative opportunities for the growth of robotic assisted surgery segment.\nThe artificial intelligence in healthcare market is expected to witness substantial growth post-pandemic.
  • The global healthcare infrastructure has observed that, in order to develop and maintain sustainable healthcare setup, utilization of computational technologies such as artificial intelligence becomes crucial.

Market insights to rapid manufacturing; Sagentia Innovation gains accreditation for medical device manufacture

Retrieved on: 
Wednesday, May 12, 2021
Articles, Medical technology, ISO 13485, Medical equipment, Science and technology, ISO, Medical device, Innovation, Technology

b'CAMBRIDGE, England, May 12, 2021 /PRNewswire/ -- Sagentia Innovation\'s Cambridge-based R&D centre has been awarded ISO 13485 accreditation for manufacture of medical devices, enabling it to offer an adaptive and flexible production service for clients that need to get to market fast.\nIn 2008 Sagentia Innovation acquired ISO 13485 accreditation for the design and development of medical devices to client specifications.

Key Points: 
  • b'CAMBRIDGE, England, May 12, 2021 /PRNewswire/ -- Sagentia Innovation\'s Cambridge-based R&D centre has been awarded ISO 13485 accreditation for manufacture of medical devices, enabling it to offer an adaptive and flexible production service for clients that need to get to market fast.\nIn 2008 Sagentia Innovation acquired ISO 13485 accreditation for the design and development of medical devices to client specifications.
  • This new, extended accreditation enables the business to offer in-house, small-scale manufacture, which can significantly speed up product launches and provide cost efficiencies for their clients.
  • The new service offer could benefit clients across all four market verticals that Sagentia Innovation serves: Consumer; Food & Beverage; Industrial, Chemicals & Energy; and Medical.\nAs a selected participant of the UK Government\'s Ventilator Challenge, Sagentia Innovation had to ensure that it was able to quickly manufacture tens of thousands of units on-site, meeting medical device quality standards.
  • "\nThe flexibility of Sagentia Innovation\'s manufacturing capability offers further advantages for clients seeking a short production run ahead of wider rollout.

Market insights to rapid manufacturing; Sagentia Innovation gains accreditation for medical device manufacture

Retrieved on: 
Wednesday, May 12, 2021
Articles, Medical technology, ISO 13485, Medical equipment, Science and technology, ISO, Medical device, Innovation, Technology

b'CAMBRIDGE, England, May 12, 2021 /PRNewswire/ -- Sagentia Innovation\'s Cambridge-based R&D centre has been awarded ISO 13485 accreditation for manufacture of medical devices, enabling it to offer an adaptive and flexible production service for clients that need to get to market fast.\nIn 2008 Sagentia Innovation acquired ISO 13485 accreditation for the design and development of medical devices to client specifications.

Key Points: 
  • b'CAMBRIDGE, England, May 12, 2021 /PRNewswire/ -- Sagentia Innovation\'s Cambridge-based R&D centre has been awarded ISO 13485 accreditation for manufacture of medical devices, enabling it to offer an adaptive and flexible production service for clients that need to get to market fast.\nIn 2008 Sagentia Innovation acquired ISO 13485 accreditation for the design and development of medical devices to client specifications.
  • This new, extended accreditation enables the business to offer in-house, small-scale manufacture, which can significantly speed up product launches and provide cost efficiencies for their clients.
  • The new service offer could benefit clients across all four market verticals that Sagentia Innovation serves: Consumer; Food & Beverage; Industrial, Chemicals & Energy; and Medical.\nAs a selected participant of the UK Government\'s Ventilator Challenge, Sagentia Innovation had to ensure that it was able to quickly manufacture tens of thousands of units on-site, meeting medical device quality standards.
  • "\nThe flexibility of Sagentia Innovation\'s manufacturing capability offers further advantages for clients seeking a short production run ahead of wider rollout.